文献速递造血干细胞移植与细胞治疗白血病

首次完全缓解急性髓系白血病单倍体与同胞全合移植结局比较

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
PubMed 文献 · Blood Adv · 2019-01-01

该研究基于国际血液和骨髓移植研究中心数据库,比较了1205例首次完全缓解的成人急性髓系白血病患者接受单倍体移植(336例,基于移植后环磷酰胺)与同胞全合移植(869例,基于钙调神经磷酸酶抑制剂)的结局。多因素分析显示两组总生存、无白血病生存、非复发死亡、复发及II-IV级急性GVHD均无显著差异,但单倍体移植组慢性GVHD发生率显著更低(HR 0.38,95%CI 0.30-0.48,P<.001)。

要点

  • 单倍体移植与同胞全合移植在总生存、无白血病生存、非复发死亡、复发及II-IV级急性GVHD方面无显著差异。
  • 单倍体移植组慢性GVHD发生率显著低于同胞全合移植组(HR 0.38,95%CI 0.30-0.48,P<.001)。
  • 亚组分析提示慢性GVHD降低不限于特定移植物来源或预处理强度。

核心结论

  • 在首次完全缓解的成人急性髓系白血病患者中,基于移植后环磷酰胺的单倍体移植较采用钙调神经磷酸酶抑制剂预防GVHD的同胞全合移植,慢性GVHD发生率更低,其他结局相似。
  • 单倍体移植是此类患者同胞全合移植的可行替代方案。

研究设计与样本

  • 研究利用国际血液和骨髓移植研究中心数据库,纳入2008-2015年1205例首次完全缓解的成人急性髓系白血病患者。
  • 336例接受基于移植后环磷酰胺的单倍体移植,869例接受基于钙调神经磷酸酶抑制剂预防GVHD的同胞全合移植。

主要发现

  • 单倍体移植组较同胞全合移植组更多采用减低强度预处理(65% vs 30%)和骨髓移植物(62% vs 7%)。
  • 多因素分析显示两组总生存(P = .15)、无白血病生存(P = .50)、非复发死亡(P = .16)、复发(P = .90)及II-IV级急性GVHD(P = .98)均无显著差异。
  • 单倍体移植组慢性GVHD发生率显著低于同胞全合移植组(HR 0.38;95%CI 0.30-0.48;P < .001)。
  • 按预处理强度和移植物来源的亚组分析提示,单倍体移植中慢性GVHD发生率降低不限于特定移植物来源或预处理强度。
  • 中心效应及微小残留病与供者类型的交互作用不是结局的预测因素。

关键数值与推荐

  • 单倍体移植组慢性GVHD风险比HR 0.38(95%CI 0.30-0.48;P < .001),低于同胞全合移植组。
  • 两组总生存P = .15,无白血病生存P = .50,非复发死亡P = .16,复发P = .90,II-IV级急性GVHD P = .98。

临床怎么用

  • 对于首次完全缓解的成人急性髓系白血病患者,基于移植后环磷酰胺的单倍体移植可作为同胞全合移植的可行替代方案。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy-based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease-donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy-based Haplo-HCT vs MSD using calcineurin inhibitor-based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rashidi A, Hamadani M, Zhang MJ, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019. PMID: 31201170. doi:10.1182/bloodadvances.2019000050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。